EUCTR2015-000934-31-EE进行中（未招募）1 期
A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot Ulcer
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient will be eligible for study participation if he/she meets the following criteria before enrollment:
- •1. Is aged = 18 and = 85 years.
- •2. Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.
- •3. Has at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America guidelines for the Diagnosis and Treatment of Diabetic Foot Infections” (CID 2012; 54:132-173) (IDSA guidelines):
- •has = 2 manifestations of inflammation (local swelling or induration, erythema, local tenderness or pain, local warmth, purulent discharge (thick, opaque to white or sanguineous secretion)
- •has = 1 of the following characteristics: erythema > 2cm, or involving structures deeper than skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic arthritis, fasciitis)
- •For patients with multiple infected ulcers, the ulcer with the highest Diabetic Foot Infection Wound score (DFI score) must be on or below the malleolus and all infected ulcers must be completely coverable using no more than 4 sponges (sponges cannot be cut).
- •4. Has documented adequate arterial perfusion in the affected limb(s) (either palpable dorsalis pedis and posterior tibial pulses, or normal Doppler wave forms, a toe blood pressure = 45 mm Hg or participation is approved by a vascular surgeon)
- •5. Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis. [Note: The investigator is referred to Diabetes Metab Res Rev 2008; 24(Suppl 1): S145–S161 for recommendations for the diagnosis of diabetic foot osteomyelitis.]
- •6. Has received appropriate surgical debridement to remove all gangrenous tissue.
- •7. If female, is nonpregnant (negative pregnancy test results at the baseline/randomization visit) and nonlactating.
- •8. If female, is either not of childbearing potential (defined as postmenopausal for = 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing 1 of the following medically acceptable methods of birth control and agrees to continue with the regimen throughout the duration of the study:
- •Oral, implantable or injectable contraceptives for 3 consecutive months before the baseline/randomization visit.
- •Total abstinence from sexual intercourse (= 1 complete menstrual cycle before the baseline/randomization visit).
- •Intrauterine device (IUD).
- •Double barrier method (condoms, sponge, diaphragm or vaginal ring with spermicidal jellies or cream).
- •9. Is willing and able to return to the study facility for all follow-up visits.
- •10. Is able to fluently speak and understand the local language and is able to provide meaningful written informed consent for the study.
- •Once baseline clinical laboratory results become available, a patient will continue to be eligible for study participation after enrollment if he or she meets the following criteria:
- •11. Has the following laboratory values
- •white blood cells (WBC) = 4000 cells/mm3 and/or absolute neutrophil count (ANC) = 1500 cells/mm3
- •hematocrit > 25%,
- •hemoglobin > 8 g/L,
- •platelet count > 75 000/mm3
- •coagulation test results less than 1.5 times the upper limit of normal (unless on anticoagulant therapy).
- •Any subject whose baseline laboratory results fall outside of these parameters will be withdrawn from the study.
- •Are the trial subjects under
排除标准
- •A patient will be excluded from the study if he/she meets any of the following criteria:
- •1. Has a known history of hypersensitivity to gentamicin (or other aminoglycosides).
- •2. Has a known or suspected hypersensitivity to bovine collagen.
- •3. Has an ulcer infection which, based upon the patient’s known history of hypersensitivity and/or as otherwise in the opinion of the investigator, cannot be adequately treated with at least one of the empiric systemic antibiotic regimens allowed by this protocol.
- •4. Has an ulcer associated with prosthetic material or an implanted device.
- •5. Has received any systemic or topical antibiotic therapy for any reason within 7 days of randomization unless it was administered to specifically treat the infected ulcer(s) and only within 36 hours of randomization.
- •6. Requires or is likely to require treatment with any concomitant topical product or wound therapy before the first follow-up study visit.
- •7. Is severely immunocompromised, or likely to become severely immunocompromised during the study, in the opinion of the investigator.
- •8. Has a history of myasthenia gravis or other neurological condition where gentamicin use is contraindicated as determined by the investigator.
- •9. Has a history of epilepsy.
- •10. Has a history of alcohol or substance abuse in the past 12 months.
- •11. Has an uncontrolled illness that, in the opinion of the investigator, is likely to cause the patient to be withdrawn from the trial or would otherwise interfere with interpreting the results of the study.
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180